الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 177 |  |  |
| | | from | 177 | | |
Abstract
Non-Hodgkin lymphoma (NHL) is a heterogenous group of lympho-proliferative malignancies. Identification of persistent disease or relapse is most often the trigger to intensify or re-initiate anti-neoplastic therapy, respectively. The present study aimed to identify clinical and laboratory properties that can predict early relapse in patients with NHL. The study recruited 178 patients with diffuse large B-cell lymphoma. Patients were followed from the time of diagnosis until death or the end of the study.Treatment response to the 1st line chemotherapy (CHOP) in the current study included CR in 132 patients (74.2 %), PR in 16 patients (9.0 %) and primary refractory disease in 30 patients (16.8 %). At the time of the study, 67 patients (37.6 %) were in complete remission while 66 patients (37.1 %) relapsed, 13 patients (9.0 %) had stable disease and 29 patients (16.3 %) had progressive disease. The reported time to relapse was 13.7 ± 7.2 months (range: 2.0 – 39.0 months) with 38 patients (21.3 %) having early relapse and 28 patients (15.7 %) having late relapse.In the current study, the presence of bulky tumor was the only significant predictor of early relapse in univariate and multivariate analysis. In this study, using univariate analysis, extranodal sites more than 1, PS ≥ 2, Ann Arbor stage III-IV and high intermediate- high IPI were significant predictors of PFS. However, using multivariate analysis, none of these factors remains significant.Regarding overall survival, significant predictors for OS included presence of B symptoms, HCV infection, presence of more than one extranodal site, PS ≥ 2, tumore stage III-IV, High intermediate- High IPI, elevated LDH and early relapse. However, in multivariate analysis, only early relapse remained significant.